Loading
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, active and no longer recruiting.
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant is a phase 1 interventional study registered as NCT03459170 by Bellicum Pharmaceuticals, with 15 participants planned, started 2018-02-01. Conditions recorded: Hematologic Malignancy. Interventions recorded: BPX-501 T cells and rimiducid.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/